$Organogenesis (ORGO.US)$Revenue has grown rapidly in the pa...
$Organogenesis (ORGO.US)$Revenue has grown rapidly in the past 5 years, with an average growth rate of 17.9%, shrinking slightly by 3.5% in 2022. Operating profit reversed losses in 2020, reaching a high of 72 million yuan in 2021, a sharp decline of 69% in 2022, and similar in net profit. It reached a high of 94 million yuan in 2021, and fell sharply by 83.5% to 0.15.5 million in 2022.
The income statement shows that although revenue declined in 2022, operating expenses continued to grow rapidly, causing a sharp decline in operating profit. Interest costs account for 9% of operating profit, so the burden is not too heavy.
2023Q1 revenue increased 10.8%, and operating profit entered the loss range. This was also due to the rapid increase in operating expenses. It seems that the company's ability to control expenses is very poor.
The balance ratio fell from 71.3% to 40.9% over the past 5 years.
The balance ratio shows that the ratio and growth rate of accounts receivable and inventory are relatively normal. Long-term loans of 66 million yuan account for 25% of net assets, and the leverage ratio is normal.
The cumulative net operating cash flow over the past 5 years is still a net outflow. There is also a large net outflow of cash flow investment, which has not generated shareholders' surpluses.
Currently, the price-earnings ratio is 31.8 times, and the price-earnings ratio is 34.6 times TTM. You can observe a few more financial reports and focus on whether the share of operating expenses has improved before making a judgment.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
